Iron Overload Disorders: Pathophysiology, Symptoms, Diagnosis, and Evidence-Based Management Strategies for Safety

Iron overload disorders describe clinical states in which excess iron accumulates in tissues, catalyzing oxidative damage and progressive organ dysfunction. The central concept is an imbalance between intestinal iron absorption, iron storage capacity, and iron export. Under normal physiology, iron homeostasis is regulated largely by hepcidin, a hepatic peptide that binds ferroportin on enterocytes and macrophages, limiting iron efflux. In iron overload, hepcidin signaling is insufficient or overridden, enabling continued iron absorption and release despite adequate or elevated total body stores.

The most recognized hereditary cause is hereditary hemochromatosis, typically due to HFE gene variants (commonly C282Y). Other genetic and non-genetic mechanisms include juvenile hemochromatosis (HJV, HAMP, or TFR2 pathways), ferroportin disease (SLC40A1), and secondary iron overload from chronic transfusion (e.g., thalassemia major) or repeated parenteral iron. In transfusion-driven overload, each transfused unit supplies substantial iron, progressively saturating transferrin. When transferrin becomes insufficient, non–transferrin-bound iron rises, increasing delivery to parenchymal cells and promoting hydroxyl radical generation via Fenton chemistry.

Pathophysiologically, excess iron drives oxidative stress, lipid peroxidation, DNA damage, and inflammatory signaling. Clinically, affected organs include the liver, pancreas, heart, endocrine glands, joints, and skin. Liver manifestations range from asymptomatic transaminitis to cirrhosis and hepatocellular carcinoma risk. Endocrine effects can lead to diabetes mellitus, hypogonadism, hypothyroidism, and adrenal insufficiency, reflecting iron deposition and tissue injury. Cardiac involvement may present as restrictive or dilated cardiomyopathy, arrhythmias, and congestive heart failure. Arthropathy, frequently involving the second and third metacarpophalangeal joints, is common and may mimic inflammatory arthritis but is often characterized by non-erosive changes.

Symptoms are often insidious. Patients may report fatigue, abdominal discomfort, joint pain, skin hyperpigmentation, erectile dysfunction, and reduced libido. Laboratory patterns typically show elevated serum ferritin and transferrin saturation. Ferritin is an acute-phase reactant and can be elevated in inflammation or liver injury, so interpretation must consider comorbid conditions. Transferrin saturation is calculated from serum iron divided by total iron-binding capacity; values persistently above threshold (commonly >45% in many guidelines) increase suspicion for hereditary disease.

Diagnosis begins with fasting iron studies and evaluation for secondary causes. If transferrin saturation and ferritin are elevated, clinicians often test HFE genotype in appropriate populations and assess liver status with elastography and/or MRI-based liver iron quantification. MRI can noninvasively estimate iron concentration in liver and myocardium, improving risk stratification. Liver biopsy is less common where imaging is available but remains valuable in select cases to stage fibrosis or evaluate alternative diagnoses.

Management aims to prevent iron-mediated injury by reducing total body iron and lowering circulating lab markers. For hereditary hemochromatosis, first-line therapy is typically therapeutic phlebotomy, performed at an individualized frequency (often weekly) until iron depletion is achieved, followed by maintenance. Phlebotomy removes iron via red cell loss, effectively bypassing hepcidin-independent absorption pathways. Targets usually include ferritin normalization or near-normal values and maintenance of safe hemoglobin levels.

For patients who cannot tolerate phlebotomy (e.g., severe anemia, some transfusion-dependent disorders without compatible protocols), iron chelation is used. Chelators such as deferoxamine, deferasirox, and deferiprone bind excess iron and facilitate urinary or fecal excretion. Chelation is central in transfusional iron overload and must be monitored for renal, hepatic, hematologic, or gastrointestinal adverse effects depending on agent. In secondary iron overload, adherence to chelation thresholds is guided by ferritin, liver iron burden, and clinical context.

Because iron overload increases liver cancer risk in advanced fibrosis, surveillance strategies may be required, including imaging and alpha-fetoprotein testing in cirrhotic patients per guideline frameworks. Lifestyle counseling can support outcomes: patients are advised to avoid excessive vitamin C supplementation (which can increase iron absorption), limit alcohol intake to reduce hepatic injury, and ensure immunizations against encapsulated organisms when splenectomy or advanced liver disease is present. Family screening is critical for hereditary forms, enabling early identification of at-risk relatives.

Prognosis improves substantially when diagnosis occurs before irreversible fibrosis and when iron reduction is maintained. Nonetheless, ongoing monitoring for metabolic, cardiac, and hepatic complications remains essential because tissue injury may progress even as serum markers normalize.

Source: @KeepORsavage